The recently released study from Fact.MR includes comprehensive information on the price points of major carglumic acid manufacturers positioned across regions, sales growth, production capacity, and speculative technological advancement.
Fact.MR, a provider of competitive intelligence and market research: Fact.MR, a business that provides competitive intelligence and market research, projects that the global demand for carglumic acid will reach US$ 152.5 million in 2023 and grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2033.
Carglumic acid's demand and popularity have significantly expanded as a result of its application in treating urea cycle issues. Lack of any one of the hepatic enzymes involved in ammonia detoxification or both transporters causes urea cycle disorders. Furthermore, this causes severe brain damage that can only be prevented by avoiding the buildup of ammonia, the most toxic metabolite.
With a high degree of toxicity for central nervous system delays, hyperammonemia is regarded as a common neonatal emergency. These days, carglumic acid is being used more often to treat a number of conditions, such as hyperammonemia, ammonia intoxication, brain damage prevention, cancer cell suppression, and apoptosis.
Key Takeaways from Market Study
- U.S. continues to be the prominent consumer of carglumic acid and is the leading producer of drugs
- Prominent market players include Apothecon Pharmaceuticals Pvt Ltd, Manus Aktteva Biopharma LLP, and Civentichem LLC
- Oral disintegrating tablets are expected to grow at a CAGR of 7.2% in the global market, where they account for nearly half of the demand
- Key Players are opting to increase investment in R&D for drug development and innovation to gain a competitive edge
- The global carglumic acid market is expected to propel at a CAGR of 7.5% by the end of the forecast period
“Investments in R&D, Drug Development, Mounting Healthcare Expenditure, and Evolving Pharmaceutical Industry are likely to Drive Market Growth” says a Fact.MR analyst
Key Strategies by Manufacturers
Prominent carglumic acid manufacturers are
- Apothecon Pharmaceuticals Pvt Ltd.
- Manus Aktteva Biopharma LLP
- Civentichem LLC
- Dipharma Francis S.r.l
- Recordati Rare Diseases
The global market for carglumic acid has a few significant competitors and is moderately competitive. A few of the major players are now leading the market in terms of sales and are employing a variety of techniques, such as acquiring other businesses to strengthen their market positions globally.
Numerous players are focusing on getting approval for generic products. For instance, the growth of API producers like Suven and Apothecan in India creates income by delivering the API to satisfy the need for carglumic acid, which propels the market growth.
- In December 2021, ANI Pharmaceuticals and Eton Pharmaceuticals announced the commercial availability of carglumic acid tablets. The drug is the first and only generic version of Carbaglu that is approved by the FDA. The FDA gave it the go-ahead to treat acute and chronic hyperammonemia brought on by a lack of N-acetyl glutamate synthase (NAGS).
View Full Report: https://www.globenewswire.com/news-release/2023/05/16/2670173/0/en/Carglumic-Acid-Market-Size-to-Reach-US-314-4-million-in-2033-Treatment-of-Hyperammonemia-to-Drive-the-Market-Growth-Fact-MR-s-Study.html
Comments
0 comment